October 7, 2016 / 1:57 PM / 9 months ago

BRIEF-Beigene says updated data continue to show that BGB-3111 is well-tolerated

1 Min Read

Oct 7 (Reuters) - Beigene Ltd:

* Presents updated clinical data on BTK inhibitor BGB-3111 in patients with Waldenstrom'S macroglobulinemia at 9th international workshop on Waldenstrom'S macroglobulinemia

* Updated data continue to show that BGB-3111 is well-tolerated and highly active in Waldenström's macroglobulinemia

* "We look forward to commencing a global phase iii study comparing BGB-3111 with Ibrutinib in WM patients this year" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below